NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...

NRX invested $27 million in its subsidiary HOPE therapeutics to fund a nationwide rollup of Interventional Psychiatry Clinics. The agreement includes an immediate $2 million investment with a ...

NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first step in a $27.0M financing to fund the planned acquisition ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. The stock rose Thursday to $2.92, reaching a six-month high.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a Delaware-based pharmaceutical company with a market capitalization of $61.63 million, announced the immediate resignation of Janet Rehnquist from its ...

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP), a clinical-stage biopharmaceutical leader, is at the forefront of addressing critical mental health challenges, including suicidal depression ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...